TIDMPXS

RNS Number : 0256M

Provexis PLC

11 September 2019

11 September 2019

Provexis plc

("Provexis" or the "Company")

Grant of Share Options

Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow(R) heart-health functional food ingredient, announces that it has today awarded a total of 62,500,000 options ('Options') over ordinary shares of 0.1 pence each in the Company ('Ordinary Shares') under the Provexis 2005 share option scheme to certain directors and scientific, sales and marketing consultants to the Company.

These Options will have an exercise price of 0.30 pence, being the closing mid-market price on 10 September 2019, and they are subject to performance criteria (including Ordinary Share price appreciation). The Options are exercisable, subject to vesting, between 1 April 2022 and 10 years from the date of grant.

A total of 58,000,000 Options have been awarded to the following directors:

 
 Director                  No. of options     Existing         Total no.       Total Options 
                                  granted       no. of        of options     as a percentage 
                                               options     over Ordinary    of the Company's 
                                                          Shares ('Total        issued share 
                                                               Options')             capital 
 Dawson Buck - Chairman         8,000,000   17,000,000        25,000,000                1.26 
                          ---------------  -----------  ----------------  ------------------ 
 Ian Ford - CEO & 
  CFO                          25,000,000   25,000,000        50,000,000                2.52 
                          ---------------  -----------  ----------------  ------------------ 
 Niamh O'Kennedy - 
  CSO                          25,000,000   13,000,000        38,000,000                1.92 
                          ---------------  -----------  ----------------  ------------------ 
 

Following the issue of the new Options, the total number of Ordinary Shares under option which could be issued if all of the performance criteria are met is 193,500,000 Ordinary Shares, representing 9.8 per cent. of the Company's issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them are set out below pursuant to the EU Market Abuse regulation.

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                        Dawson Buck - Chairman 
                                   Ian Ford - CEO & CFO 
                                   Niamh O'Kennedy - CSO 
     --------------------------  ---------------------------------------------------------- 
 2    Reason for the notification 
     -------------------------------------------------------------------------------------- 
 a)   Position/status             See 1 a) above 
     --------------------------  ---------------------------------------------------------- 
 b)   Initial notification        Initial notification 
       / 
       Amendment 
     --------------------------  ---------------------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     -------------------------------------------------------------------------------------- 
 a)   Name                        PROVEXIS PLC 
     --------------------------  ---------------------------------------------------------- 
 b)   LEI                         21380042E3Y3N9VZ6N48 
     --------------------------  ---------------------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for (i) 
       each type of instrument; (ii) each type of transaction; (iii) 
       each date; and (iv) each place where transactions have been 
       conducted 
     -------------------------------------------------------------------------------------- 
 a)   Description of the          Ordinary Shares of 0.1p each 
       financial instrument, 
       type of 
       instrument 
                                   ISIN: GB00B0923P27 
       Identification code 
     --------------------------  ---------------------------------------------------------- 
 b)   Nature of the transaction   Grant of options over ordinary shares 
     --------------------------  ---------------------------------------------------------- 
 c)   Price(s) and volume(s)       Director/PDMR                     Price(s)    Volume(s) 
                                    Dawson Buck - Chairman     0.30p per share    8,000,000 
                                                             -----------------  ----------- 
                                    Ian Ford - CEO & 
                                     CFO                       0.30p per share   25,000,000 
                                                             -----------------  ----------- 
                                    Niamh O'Kennedy - 
                                     CSO                       0.30p per share   25,000,000 
                                                             -----------------  ----------- 
     --------------------------  ---------------------------------------------------------- 
 d)   Aggregated information        Price(s)            Volume(s) 
       - Aggregated volume           0.30p per share    58,000,000 
       - Price                                         ----------- 
     --------------------------  ---------------------------------------------------------- 
 e)   Date of the transaction     11 September 2019 
     --------------------------  ---------------------------------------------------------- 
 f)   Place of the transaction    Outside a trading venue 
     --------------------------  ---------------------------------------------------------- 
 

For further information please contact:

 
 Provexis plc                  Tel: 07490 391888 
  Dawson Buck, Chairman         enquiries@provexis.com 
  Ian Ford, CEO & CFO 
 Allenby Capital Limited       Tel: 020 3328 5656 
  Nick Naylor / Liz Kirchner 
 

Notes for editors

About Provexis plc

AIM-listed Provexis is focused on the development, licensing and sales of its proprietary, scientifically-proven Fruitflow(R) heart-health functional food ingredient.

Provexis was founded in 1999 and is headquartered in Reading, Berkshire.

Provexis shares are traded on the AIM market of the London Stock Exchange under the ticker symbol PXS.

For further information, please visit www.provexis.com and www.fruitflowplus.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHEFLFFKKFBBBB

(END) Dow Jones Newswires

September 11, 2019 11:02 ET (15:02 GMT)

Provexis (LSE:PXS)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Provexis.
Provexis (LSE:PXS)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Provexis.